Syndax Pharmaceuticals Faces Major Setback as Pulmonary Fibrosis Trial Fails
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced on October 12 that it will discontinue development of its investigational drug axatilimab for idiopathic pulmonary fibrosis (IPF) after a phase‑II study failed to meet its primary endpoint. The decision follows the company’s disclosure that the mid‑stage trial—an essential step toward expanding the therapeutic use of its approved drug axitinib—did not achieve the expected benefit in patients with chronic lung scarring.
Trial Outcome and Immediate Consequences
The phase‑II study, conducted in a global, randomized, double‑blind design, evaluated axatilimab in 120 IPF patients over 52 weeks. The primary efficacy measure was improvement in forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO). Results showed no statistically significant difference between the axatilimab and placebo arms, leading Syndax to terminate the program.
Following the announcement, Syndax’s stock fell sharply. By 10:30 ET on Tuesday, the shares were trading down 17 %, a steep drop that reflected investor concern over the company’s pipeline viability. The decline mirrored broader market pressure on biotech names, as noted in contemporaneous coverage of the S&P 500’s modest 0.1 % decline amid a flurry of bank earnings reports.
Analyst Response
Despite the setback, several analysts maintained a bullish stance on Syndax. Stifel, a leading investment bank, reaffirmed its Buy recommendation after the trial failure, citing the company’s strong balance sheet and its ongoing efforts to diversify beyond the IPF asset. Stifel’s analysis highlighted that the failure did not negate the potential of Syndax’s core oncology programs, particularly its solid‑tumor pipeline, which remains in earlier development stages.
Other analysts echoed this sentiment. Bloomberg and Reuters reported that the company’s market cap remains robust at $1.52 billion, with a 52‑week high of $25.59 and a low of $12.99. The firm’s price‑earnings ratio is currently negative (–6.74), reflecting the high investment in research and development typical of a biopharmaceutical company.
Broader Market Context
The IPF trial failure occurred amid a turbulent trading day for U.S. equities. While bank earnings reports and chipmaker performance dominated headlines, the biotech sector endured a broader sell‑off. Market analysts noted that, even as banks reported mixed results, the S&P 500’s futures remained largely unchanged, suggesting that the broader market was primarily reacting to company‑specific news rather than macroeconomic data.
Looking Ahead
Syndax’s leadership has pledged to focus resources on its other therapeutic areas, including solid tumors and hematologic malignancies, where the company has active programs. The firm’s website, www.syndax.com , continues to detail its research priorities, emphasizing a commitment to developing targeted therapies for cancer patients in the United States.
Investors and market watchers will be monitoring Syndax’s next quarterly earnings for updates on its oncology pipeline, potential partnership talks, and any new clinical milestones that could offset the disappointment from the IPF trial.
